# Latigo Biotherapeutics, Inc. (LTGO)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/latigo-biotherapeutics-inc/ JSON: https://steadybase.io/company/latigo-biotherapeutics-inc.json Checked Nov 21, 2026. Latest filing read: Nov 5, 2026.

## Company

- Legal name: Latigo Biotherapeutics, Inc.
- Ticker: LTGO (Nasdaq)
- SEC CIK: 0002056611
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Thousand Oaks, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Website: latigobio.com
- Investor relations: https://investors.latigobio.com/
- LinkedIn: https://www.linkedin.com/company/latigobio
- Next earnings date: Dec 3, 2026

## Key facts

- Shares outstanding: 66,299,347 as of Nov 2, 2026 (10-Q filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/2056611/000119312526448582/0001193125-26-448582-index.html

## Business

Disrupt Pain Without Opioids. While other treatments dull pain, Latigo’s solutions target the source of pain before it reaches the central nervous system. The result is healing without dependence, and relief that can help restore quality of life.

Source: Company website description, https://latigobio.com/

## Officers and directors

- Todd N. Smith, President and CEO. Source: Form 4 filed Nov 18, 2026, https://www.sec.gov/Archives/edgar/data/2056611/000152367226000010/0001523672-26-000010-index.htm
- Nima Farzan, President and CEO. LinkedIn: https://linkedin.com/in/nima-farzan-bb293. Source: Form 3 filed Aug 6, 2026, https://www.sec.gov/Archives/edgar/data/2056611/000180829626000006/0001808296-26-000006-index.htm
- Neha Krishnamohan, CFO and Chief Business Officer. LinkedIn: https://linkedin.com/in/neha-krishnamohan. Source: Form 3 filed Aug 6, 2026, https://www.sec.gov/Archives/edgar/data/2056611/000186617126000002/0001866171-26-000002-index.htm
- Neil Singla, Chief Medical Officer. LinkedIn: https://linkedin.com/in/neil-singla-md. Source: Form 3 filed Aug 6, 2026, https://www.sec.gov/Archives/edgar/data/2056611/000214374126000002/0002143741-26-000002-index.htm

## Recent 8-K events

- Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2056611/000119312526448537/ltgo-20261103.htm
- Sep 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2056611/000119312526381912/ltgo-20260903.htm
- Aug 10, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2056611/000119312526342321/d170764d8k.htm

## Insider trades (Form 4)

- Aug 10, 2026: James B. Tananbaum (Director) bought 140,000 shares, about $2.5M. Source: https://www.sec.gov/Archives/edgar/data/2056611/000158175426000006/0001581754-26-000006-index.htm

## What management said

- "With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program" Todd N. Smith, president and chief executive officer, Latigo (8-K filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/2056611/000119312526448537/ltgo-ex99_1.htm

## Latest filings

- 8-K filed Sep 3, 2026: https://www.sec.gov/Archives/edgar/data/2056611/000119312526381912/ltgo-20260903.htm
- 10-Q filed Sep 3, 2026: https://www.sec.gov/Archives/edgar/data/2056611/000119312526381969/ltgo-20260630.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

